AMEX · Biotechnology

AEON Biopharma, Inc. (AEON) Stock

$0.24 -5.50% AMEX: AEON Healthcare

AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions.

Valuation

MetricValue
Price$0.24
Market Cap$2.80M
P/E Ratio-0.05
P/B Ratio-0.18
P/S Ratio0.00
EPS (TTM)$-3.95
52-Week High$1.45
52-Week Low$0.22
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE223.66%
ROA-696.52%
ROCE-932.13%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity-0.16
Current Ratio0.43

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-66.0M$-48.0M$-348.0M$73.0M$-13.0M
Net Profit$-56.0M$-53.0M$-385.0M$42.0M$-39.0M
EPS$-31.73$-27.25$-4.99$72.93$-3.95
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$6.0M$11.0M$7.0M$3.0M$6.0M
Total Liabilities$230.0M$281.0M$160.0M$32.0M$61.0M
Cash$5.0M$10.0M$5.0M$0$3.0M
Borrowings$87.0M$132.0M$0$13.0M$36.0M

Latest News

Aeon Biopharma Prices $13.8 Million Underwritten Public Offering MT Newswires · Jul 14, 2026 AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding GlobeNewswire · Jul 14, 2026 AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society GlobeNewswire · Jun 4, 2026 Cervical Dystonia Market to Witness Robust Growth During the Forecast Period (2026-2036) Driven by the Expanding Therapeutic Options | DelveInsight PR Newswire · Jun 2, 2026 Why You Might Be Interested In Aeon Co. (M) Bhd. (KLSE:AEON) For Its Upcoming Dividend Simply Wall St. · May 25, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-28.0M$-36.0M$-48.0M$-20.0M$-17.0M
Investing Cash Flow$0$-1.0M$0$0$0
Financing Cash Flow$-1.0M$0$0$0$2.0M
Net Cash Flow$-15.0M$5.0M$-5.0M$-5.0M$3.0M
Free Cash Flow$-29.0M$-36.0M$-48.0M$-20.0M$-17.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA0.02
FCF Yield-606.58%
Quick Ratio0.43
Interest Coverage0.00
Return 1Y-62.49%
Return 3Y-99.95%
Return 5Y—

Ownership

Insiders Held45.68%
Institutions Held3.25%
Institutions Float Held5.98%
Institutional HolderSharesReport Date
Dauntless Investment Group, LLC 2,527,7752026-03-31
Vanguard Capital Management LLC90,5292026-03-31
Geode Capital Management, LLC87,0622026-03-31
Blue Owl Capital Holdings LP42,3532026-03-31
Xtx Topco Ltd20,4242026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About AEON Biopharma, Inc.

AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc. in December 2019. Established in 2012, the company maintains its principal operations from Newport Beach, California.

AEON Biopharma, Inc. is led by CEO Robert Bancroft, employs 5 people, headquartered in US, publicly traded since 2023.

AEON Biopharma, Inc. (AEON) stock trades at $0.24 with a market capitalization of $2.80M. The stock is valued at a price-to-earnings (P/E) ratio of -0.05, price-to-book of -0.18, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.22 and $1.45, and currently trades 83.4% below its 52-week high.

On profitability, AEON Biopharma, Inc. generates a return on equity (ROE) of 223.66% — well above the market average, a sign of a high-quality business, return on capital employed of -932.13%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.aeonbiopharma.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides